Ribonucleases are evoking medical interest because of their intrinsic cytotoxic activity. Most notably, ranpirnase, which is an amphibian ribonuclease, is in advanced clinical trials as a chemotherapeutic agent for the treatment of cancer. Here, we describe a strategy to create a novel antiviral agent based on bovine pancreatic ribonuclease (RNase A), a mammalian homologue of ranpirnase. Specifically, we have linked the N- and C-termini of RNase A with an amino acid sequence that is recognized and cleaved by human immunodeficiency virus (HIV) protease. This linkage obstructs the active site, forming an HIV-specific RNase A zymogen. Cleavage by HIV-1 protease increases ribonucleolytic activity by 50-fold. By relying on the proper function of HIV-1 protease, rather than its inhibition, our approach will not engender known mechanisms of resistance. Thus, we report an initial step toward a new class of agents for the treatment of HIV/AIDS.
Get full access to this article
View all access options for this article.
References
1.
HymesKB, CheungT, GreeneJBet al.Kaposi's sarcoma in homosexual men—a report of eight cases. Lancet, 1981; 2:598–600.
2.
CarrA. Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov, 2003; 2:624–634.
3.
MatthewsT, SalgoM, GreenbergM, ChungJ, DeMasiR, BolognesiD. Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov, 2004; 3:215–225.
4.
HansonK, HicksC. New antiretroviral drugs. Curr HIV/AIDS Rep, 2006; 3:93–101.
5.
BarbaroG, ScozzafavaA, MastrolorenzoA, SupuranCT. Highly active antiretroviral therapy: Current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des, 2005; 11:1805–1843.
6.
TemesgenZ, WarnkeD, KastenMJ. Current status of antiretroviral therapy. Expert Opin Pharmacother, 2006; 7:1541–1554.
7.
KellermanS, BegleyE, BoyettB, ClarkH, SchuldenJ. Changes in HIV and AIDS in the United States: Entering the third decade. Curr Infect Dis Rep, 2005; 7:138–143.
8.
WeissRA. HIV and AIDS: Looking ahead. Nat Med, 2003; 9:887–891.
9.
FlexnerC. HIV drug development: The next 25 years. Nat Rev Drug Discov, 2007; 6:959–966.
10.
AgrawalL, LuX, JinQ, AlkhatibG. Anti-HIV therapy: Current and future directions. Curr Pharm Des, 2006; 12:2031–2055.
11.
ShaferRW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev, 2002; 15:247–277.
12.
SimonV, HoDD. HIV-1 dynamics in vivo: Implications for therapy. Nat Rev Microbiol, 2003; 1:181–190.
13.
YangQE. Human immunodeficiency virus reservoir might be actively eradicated as residual malignant cells by cytotoxic chemotherapy. Med Hypotheses, 2004; 62:358–363.
14.
RavotE, LisziewiczJ, LoriF. New uses for old drugs in HIV infection: The role of hydroxyurea, cyclosporin and thalidomide. Drugs, 1999; 58:953–963.
15.
KohlNE, EminiEA, SchleifWAet al.Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA, 1988; 85:4686–4690.
16.
Vocero-AkbaniAM, HeydenNV, LissyNA, RatnerL, DowdySF. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med, 1999; 5:29–33.
17.
FalnesPO, WelkerR, KrausslichHG, OlsnesS. Toxins that are activated by HIV type-1 protease through removal of a signal for degradation by the N-end-rule pathway. Biochem J, 1999; 343,Pt 1:199–207.
18.
RainesRT. Ribonuclease A. Chem Rev, 1998; 98:1045–1065.
19.
MarshallGR, FengJA, KusterDJ. Back to the future: Ribonuclease A. Biopolymers, 2008; 90:259–277.
20.
D'AlessioG, RiordanJF. Ribonucleases: Structures, Functions. Academic Press: New York, 1997.
21.
MatousekJ. Ribonucleases and their antitumor activity. Comp Biochem Physiol, 2001; 129C:175–191.
22.
LelandPA, RainesRT. Cancer chemotherapy—ribonucleases to the rescue. Chem Biol, 2001; 8:405–413.
23.
MakarovAA, IlinskayaON. Cytotoxic ribonucleases: Molecular weapons and their targets. FEBS Lett, 2003; 540:15–20.
24.
BenitoA, RibóM, VilanovaM. On the track of antitumor ribonucleases. Mol Biosyst, 2005; 1:294–302.
25.
ArnoldU, Ulbrich-HofmannR. Natural and engineered ribonucleases as potential cancer therapeutics. Biotechnol Lett, 2006; 28:1615–1622.
26.
LeeJE, RainesRT. Ribonucleases as novel chemotherapeutics: The ranpirnase example. BioDrugs, 2008; 22:53–58.
27.
ArdeltW, MikulskiSM, ShogenK. Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. J Biol Chem, 1991; 266:245–251.
28.
PavlakisN, VogelzangNJ. Ranpirnase—an antitumour ribonuclease: Its potential role in malignant mesothelioma. Expert Opin Biol Ther, 2006; 6:391–399.
29.
YouleRJ, WuYN, MikulskiSMet al.RNase inhibition of human immunodeficiency virus infection of H9 cells. Proc Natl Acad Sci USA, 1994; 91:6012–6106.
30.
BedoyaVI, BoassoA, HardyAW, RybakS, ShearerGM, RugelesMT. Ribonucleases in HIV type 1 inhibition: Effect of recombinant RNases on infection of primary T cells and immune activation-induced RNase gene and protein expression. AIDS Res Hum Retroviruses, 2006; 22:897–907.
31.
PlainkumP, FuchsSM, WiyakruttaS, RainesRT. Creation of a zymogen. Nat Struct Biol, 2003; 10:115–119.
32.
JohnsonRJ, LinSR, RainesRT. A ribonuclease zymogen activated by the NS3 protease of the hepatitis C virus. FEBS J, 2006; 273:5457–5465.
33.
LozzioCB, LozzioBB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood, 1975; 45:321–334.
34.
IdoE, HanHP, KezdyFJ, TangJ. Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S. J Biol Chem, 1991; 266:24359–24366.
SmithBD, SoellnerMB, RainesRT. Potent inhibition of ribonuclease A by oligo(vinylsulfonic acid)J Biol Chem, 2003; 278:20934–20938.
37.
MildnerAM, RothrockDJ, LeoneJWet al.The HIV-1 protease as enzyme and substrate: Mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. Biochemistry, 1994; 33:9405–9413.
38.
DavisDA, DorseyK, WingfieldPTet al.Regulation of HIV-1 protease activity through cysteine modification. Biochemistry, 1996; 35:2482–2488.
39.
PanSH, MalcolmBA. Reduced background expression and improved plasmid stability with pET vectors in BL21 (DE3)Biotechniques, 2000; 29:1234–1238.
40.
ToddMJ, SemoN, FreireE. The structural stability of the HIV-1 protease. J Mol Biol, 1998; 283:475–488.
41.
LavisLD, RutkoskiTJ, RainesRT. Tuning the pKa of fluorescein to optimize binding assays. Anal Chem, 2007; 79:6775–6782.
42.
RutkoskiTJ, KurtenEL, MitchellJC, RainesRT. Disruption of shape-complementarity markers to create cytotoxic variants of ribonuclease A. J Mol Biol, 2005; 354:41–54.
43.
PettitSC, MoodyMD, WehbieRSet al.The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol, 1994; 68:8017–8027.
44.
PettitSC, LindquistJN, KaplanAH, SwanstromR. Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology, 2005; 2:66.
45.
KlinkTA, RainesRT. Conformational stability is a determinant of ribonuclease A cytotoxicity. J Biol Chem, 2000; 275:17463–17467.
46.
HuiJO, TomasselliAG, Zurcher-NeelyHA, HeinriksonRL. Ribonuclease A as a substrate of the protease from human immunodeficiency virus-1. J Biol Chem, 1990; 265:21386–21389.
47.
SuhasiniAN, SirdeshmukhR. Transfer RNA cleavages by onconase reveal unusual cleavage sites. J Biol Chem, 2006; 281:12201–12209.
48.
LelandPA, SchultzLW, KimB-M, RainesRT. Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci USA, 1998; 98:10407–10412.
49.
RutkoskiTJ, RainesRT. Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity. Curr Pharm Biotechnol, 2008; 9:185–199.
50.
KobeB, DeisenhoferJ. Mechanism of ribonuclease inhibition by ribonuclease inhibitor protein based on the crystal structure of its complex with ribonuclease A. J Mol Biol, 1996; 264:1028–1043.
51.
JohnsonRJ, McCoyJG, BingmanCA, PhillipsGNJr, RainesRT. Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein. J Mol Biol, 2007; 367:434–449.
52.
BjellqvistB, BasseB, OlsenE, CelisJE. Reference points for comparisons of two-dimensional maps of proteins from different human cell types defined in a pH scale where isoelectric points correlate with polypeptide compositions. Electrophoresis, 1994; 15:529–539.
53.
LeeFS, ShapiroR, ValleeBL. Tight-binding inhibition of angiogenin and ribonuclease A by placental ribonuclease inhibitor. Biochemistry, 1989; 28:225–230.
